Scope of the Study
Sleep disorders include problems with the quality, timing and amount of sleep, which cause problems with functioning and suffering during the daytime. There are different types of sleep disorders, which are insomnia, narcolepsy, obstructive sleep apnea, and restless leg syndrome and among which insomnia is the most common. According to The American Psychiatric Association in primary care, approx. 10-20 percent of people complain of significant sleep problems and about one-third of adults are having insomnia symptoms and 6-10 percent meet the criteria for insomnia disorder. In America, more than 50 million people have chronic sleep disorders.
The market study is being classified by Type (Insomnia [Short-Term Insomnia, Chronic Insomnia], Sleep Apnea, Narcolepsy, Restless Legs Syndrome and REM Sleep Behavior Disorder), by Application (Hospitals, Clinics, Research Centers and Others) and major geographies with country level break-up.
Arena Pharmaceuticals (United States), Boehringer Ingelheim (Germany), Fabre-Kramer Pharmaceuticals (United States), Jazz Pharmaceuticals (Ireland), Merck & Co (United States), Glaxo Smith Kline (United Kingdom), Respirerx Pharmaceuticals (United States), Neurocrine Biosciences (United States), Koninklijke Philips N.V. (Netherlands), Medtronic PLC (Ireland), Teva Pharmaceutical Industries Ltd. (Israel) and Vanda Pharmaceuticals Inc. (United States) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Sleep Wake Disorder market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Sleep Wake Disorder market by Type, Application and Region.
On the basis of geography, the market of Sleep Wake Disorder has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Incidence of Depression & Medical Disorder
- Rising Geriatric Population Suffering From Sleep Disorder
- High Usage of Sleep Apnea Devices and Growing Healthcare Facilities
- Introduction of Home Sleep Test Kits and Wearable Monitors
- Introduction of Continuous Positive Airway Pressure (CPAP) Therapy
- Side Effects Associated with the Drug used to Treat Sleep Wake Disorder
- Rising Investment on Research and Development of Drugs for the Sleep Wake Disorder
- Affordable Reimbursement Scenario for Drugs prescribed in Insomnia Treatment
- Patent Expiration of Sleep Disorder Treatment Drugs
Market Leaders and their expansionary development strategies
On January 16, 2020 - Merck completed the acquisition of ArQule through a merger of Merck’s wholly-owned subsidiary with and into ArQule.
On January 22, 2020 - Jazz Pharmaceuticals plc has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January, 2020 seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Key Target AudienceManufacturers of Sleep Disorder Drugs, Industry Associations, Potential Investors, Healthcare Industry, Regulatory Bodies and Governmental Bodies
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase